SCHEMBL5367152

SCHEMBL5367152

Cc1c(Br)ccc2c1C(=Cc1cc(Cl)cc(Br)c1O)C(=O)N2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 6/20 0.48
PSEN1 P49768 2/20 0.48
PSEN2 P49810 2/20 0.48
APH1B Q8WW43 2/20 0.48
NCSTN Q92542 2/20 0.48
APH1A Q96BI3 2/20 0.48
PSENEN Q9NZ42 2/20 0.48
ERN1 O75460 1/20 0.43
MDM2 Q00987 1/20 0.42
RAF1 P04049 7/20 0.41
MAP1LC3B Q9GZQ8 3/20 0.40
EGFR P00533 2/20 0.40
PLK4 O00444 2/20 0.40
PLK1 P53350 2/20 0.40
NTRK1 P04629 1/20 0.40
ARAF P10398 1/20 0.40
PIM1 P11309 1/20 0.40
BRAF P15056 1/20 0.40
CSNK2A1 P68400 1/20 0.40
PIM3 Q86V86 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362198 0.92 LRRK2 (0.45) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5369739 0.89 MAP1LC3B (0.43) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5365128 0.87 LRRK2 (0.51) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5373328 0.86 LRRK2 (0.52) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL7138246 0.82 MDM2 (0.42) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL7137559 0.82 ERN1 (0.44) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL7140872 0.82 MDM2 (0.51) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5369354 0.81 MAP3K7 (0.54) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5369742 0.81 MAP3K7 (0.45) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL5377075 0.80 NPC1 (0.42) LRRK2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK LRRK2 289/4885PSEN1 3695/4885PSEN2 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.